Epstein-Barr virus-associated gastric carcinoma: Evidence of age-dependence among a Mexican population

Roberto Herrera-Goepfert, Suminori Akiba, Chihaya Koriyama, Shan Ding, Edgardo Reyes, Tetsuhiko Itoh, Yoshie Minakami, Yoshito Eizuru

INTRODUCTION

Gastric cancer (GC) is the second leading cause among cancer deaths in the world[1] and is one of the most frequent malignant neoplasms in Mexico[2]. Although the etiology of gastric carcinoma is now accepted as multifactorial, infectious agents play a central role in the mechanism of neoplastic transformation. The bacterium Helicobacter pylori (H pylori) has been implicated in a high percentage of gastric adenocarcinomas[3], in intestinal- as well as diffuse-type adenocarcinomas, according to the Lauren histopathologic classification[4]. Another infectious agent, Epstein-Barr virus (EBV) or gamma type 4 herpes virus, has also been proved to be associated with gastric carcinoma in approximately 10% of cases[5]. This association has been reported in intestinal- and diffuse-type adenocarcinomas, as well as in nearly 100% of cases labeled lymphoid stroma-rich, lymphoepithelioma-like (LEL) carcinomas. The etiological role of EBV in GC development has been suspected on the basis of the uniform expression of Epstein-Barr nuclear antigen (EBNA)-1 protein, and EBV-encoded small non-polyadenylated RNA (EBER)-1 in all GC cells, the episcopal monoclonality of the EBV genome, the elevated serum antibodies against EBV-related antigens among EBV-GC patients, and the unique ‘lace pattern’ morphology in some

METHODS: Cases of primary gastric adenocarcinoma were retrieved from the files of the Departments of Pathology at the Instituto Nacional de Cancerología and the Instituto Nacional de la Nutrición in Mexico City. The anatomic site of the gastric neoplasia was identified, and carcinomas were histologically classified as intestinal and diffuse types and subclassified as proposed by the Japanese Research Society for Gastric Cancer. EBV-encoded small non-polyadenylated RNA-1 (EBER-1) in situ hybridization was conducted to determine the presence of EBV in neoplastic cells.

RESULTS: We studied 330 consecutive, non-selected, primary gastric carcinomas. Among these, there were 173 male and 157 female patients (male/female ratio 1.1/1). EBER-1 was detected in 24 (7.3%) cases (male/ female ratio: 1.2/1). The mean age for the entire group was 58.1 years (range: 20-88 years), whereas the mean age for patients harboring EBER-1-positive gastric carcinomas was 65.3 years (range: 50-84 years). Age and histological type showed statistically significant differences, when EBER-1-positive and -negative gastric carcinomas were compared. EBER-1 was detected in hyperplastic- and dysplastic-gastric mucosa surrounding two EBER-1-negative carcinomas, respectively.

CONCLUSION: Among Latin-American countries, Mexico has the lowest frequency of EBVaGC. Indeed, the Mexican population >50 years of age was selectively affected. Ethnic variations are responsible for the epidemiologic behavior of EBVaGC among the worldwide population.

*Key words: Epstein-Barr virus; Stomach; Lymphoepithelioma-like carcinoma; Gastric carcinoma; EBV-A; EBER-1; LMP-1

INTRODUCTION

Gastric cancer (GC) is the second leading cause among cancer deaths in the world[1] and is one of the most frequent malignant neoplasms in Mexico[2]. Although the etiology of gastric carcinoma is now accepted as multifactorial, infectious agents play a central role in the mechanism of neoplastic transformation. The bacterium Helicobacter pylori (H pylori) has been implicated in a high percentage of gastric adenocarcinomas[3], in intestinal- as well as diffuse-type adenocarcinomas, according to the Lauren histopathologic classification[4]. Another infectious agent, Epstein-Barr virus (EBV) or gamma type 4 herpes virus, has also been proved to be associated with gastric carcinoma in approximately 10% of cases[5]. This association has been reported in intestinal- and diffuse-type adenocarcinomas, as well as in nearly 100% of cases labeled lymphoid stroma-rich, lymphoepithelioma-like (LEL) carcinomas. The etiological role of EBV in GC development has been suspected on the basis of the uniform expression of Epstein-Barr nuclear antigen (EBNA)-1 protein, and EBV-encoded small non-polyadenylated RNA (EBER)-1 in all GC cells, the episcopal monoclonality of the EBV genome, the elevated serum antibodies against EBV-related antigens among EBV-GC patients, and the unique ‘lace pattern’ morphology in some
EBV-associated gastric carcinoma (EBVaGC) accounts for 1.7–16% of gastric carcinomas throughout the world, excluding LEL carcinomas. The lowest frequency has been recorded in the UK, whereas the highest was in the USA. The definitive explanation for this figure remains unclear, but is probably related with genetic variations among different populations, as well as cultural and environmental influences among different geographic regions. Among Latin Americans, Mexican individuals are less likely to develop GC in association with EBV infection; in a previous study, we reported a prevalence of 8.15% in 1980–1995 in Mexico City. The results of a partial analysis of 135 cases were published previously[7]. Eligible cases were included whenever they possessed complete demographic and pathologic information, as well as paraffin blocks with appropriate and well-preserved neoplastic tissue for molecular analysis. The age and gender of patients, and anatomic site, histological type, and depth of invasion of gastric carcinomas were obtained from records at the corresponding Department of Pathology.

**Pathologic features**

The anatomic site of gastric neoplasia was identified as upper (proximal) third, middle third, or lower (distal) third. On the basis of predominant histological pattern, carcinomas were classified as intestinal- or diffuse-type according to the Lauren criteria and subclassified as proposed by the Japanese Research Society for Gastric Cancer as follows: intestinal types tub1 (well-differentiated adenocarcinoma with distinct glandular pattern and columnar epithelium throughout, moderate or small amount of stroma); tub2 (moderately differentiated adenocarcinoma with small or incomplete tubular structures with cubical or flat epithelium, amount of stroma variable from case to case), and muc (mucinous carcinoma); diffuse types, including por1 (poorly differentiated adenocarcinoma with solid, sheet-like proliferation with an alveolar pattern and indistinct tubular differentiation), por2 (poorly differentiated adenocarcinoma with acinar and trabecular pattern, usually showing diffuse infiltration with abundant fibrous stroma), and sig (signet-ring cell carcinoma). A special category, LEL carcinoma, similar to por1 adenocarcinoma but with dense lymphoid infiltrate exceeding total mass of carcinoma cells, was included. The depth of invasion was specified as mucosa; submucosa; or muscularis propria, subserosa, or serosa.

**Materials and Methods**

**Patient population**

We retrieved cases of gastric adenocarcinoma from the files of the Departments of Pathology at the Instituto Nacional de Cancerología (1983-2000) and the Instituto Nacional de la Nutrición (1980-1995) in Mexico City. The anatomic site of gastric neoplasia was identified as upper (proximal) third, middle third, or lower (distal) third. On the basis of predominant histological pattern, carcinomas were classified as intestinal- or diffuse-type according to the Lauren criteria and subclassified as proposed by the Japanese Research Society for Gastric Cancer as follows: intestinal types tub1 (well-differentiated adenocarcinoma with distinct glandular pattern and columnar epithelium throughout, moderate or small amount of stroma); tub2 (moderately differentiated adenocarcinoma with small or incomplete tubular structures with cubical or flat epithelium, amount of stroma variable from case to case), and muc (mucinous carcinoma); diffuse types, including por1 (poorly differentiated adenocarcinoma with solid, sheet-like proliferation with an alveolar pattern and indistinct tubular differentiation), por2 (poorly differentiated adenocarcinoma with acinar and trabecular pattern, usually showing diffuse infiltration with abundant fibrous stroma), and sig (signet-ring cell carcinoma). A special category, LEL carcinoma, similar to por1 adenocarcinoma but with dense lymphoid infiltrate exceeding total mass of carcinoma cells, was included. The depth of invasion was specified as mucosa; submucosa; or muscularis propria, subserosa, or serosa.

**EBV genotyping**

**Preparation of DNA** Each formalin-fixed and paraffin-embedded specimen was cut into 10-μm-thick slices, and a DNA sample was prepared following the method reported previously[10]. Each paraffinized sample was treated with proteinase K (200 μg/mL) at 37 °C overnight followed by phenol/chloroform extraction and ethanol precipitation. Finally, the extracted DNA sample was dissolved in 50 μL of TE buffer.

**Genotype-specific primer sets and probes** Four different regions, the EBNA-3C, BamHI-F, BamHI-I, and XhoI sites in LMP-1, were used to determine viral genotypes. Types A and B can be determined by using the EBNA-2, -3A, -3B, or -3C gene[12,13]. In the present study, we chose EBNA-3C for genotyping because we experienced a higher detection rate of the primer set than those of the EBNA-2 region found in previous studies[13,14]. Types A and B, identified by PCR amplification of EBNA-3C region, corresponded to a 153- and a 246-bp band, respectively, and were confirmed by Southern blot hybridization with type-specific internal probes[14]. Wild-type F and f variants were identified by the presence of a 186-bp fragment in amplification of the BamHI F region; after BamHI cleavage, a 186-bp fragment could be identified in the case of wild-type F, and a 127-bp fragment could be identified in the case of the f variant. Wild-type F and f variants were confirmed by Southern blot hybridization with the internal probe as described previously[15].

For the BamHI-I region, a 205-bp fragment was amplified by using primer sets as described previously[17], and types C and D were distinguished after cleavage by BamHI-restriction enzyme. Type C had a 205-bp fragment, and type D had cleaved fragments with 130 and 75 bp. Types C and D were also confirmed by Southern blot hybridization with a cloned BamHI-I DNA fragment probe.

To detect the XhoI polymorphism in exon 1 of the LMP-1 gene, we amplified a 497-bp DNA fragment with a primer set as previously described[18]. When two fragments, 340- and 157-bp long, were observed after XhoI digestion of the PCR product, the case was considered to contain the XhoI cleavage site. The 497-bp fragment of the PCR product of the B95-8 cell line was used as a probe to confirm the XhoI
clease of LMP-1 by Southern blot hybridization[19].

PCR and Southern blot hybridization The PCR template contained the appropriate primer pair (1 μmol/L each), deoxyribonucleotide triphosphates (200 μmol/L each), and Taq polymerase (Takara Shuzo, Kyoto, Japan) in a total of 100 μL of PCR buffer. PCR products or PCR products digested with BamHI and XhoI were confirmed by electrophoresis in 2% agarose gel and by staining with 0.5 μg/mL of ethidium bromide. Then, electrophoretic pattern was photographed under ultraviolet light. Electrophoretic DNA was transferred onto a Hybond N+ nylon membrane (Amersham Pharmacia Biotech, UK) by capillary blotting using 0.4 N NaOH solution. Membranes were prehybridized with hybridization buffer for 0.5-1 h at 42 °C. After the probe was added, hybridization was carried out overnight at 42 °C. Probes of types A and B, and BamHI-F were labeled with Dig oligonucleotide 3'-end labeling kit and detected using a Dig luminescent detection kit (Boehringer Mannheim, Germany). For detecting the BamHI-I fragment and XhoI polymorphism in LMP-1, hybridization was carried out using the ECL direct labeling and detection kit (Amersham Pharmacia Biotech, UK) according to the manufacturer's instructions.

Statistical analysis
Odds ratios (ORs) and 95% confidence intervals (95% CIs) were obtained from logistic regression analysis, making comparisons between EBER-1-positive and EBER-1-negative gastric carcinomas with regard to age, gender, decade, anatomic site, histologic type, and depth of invasion.

RESULTS
Patient characteristics
We studied 330 consecutive, non-selected cases of gastrectomies due to primary gastric carcinoma. Among the 330 cases, there were 173 male and 157 female patients. The mean age was 58.1 years (range: 20-88 years) for all the patients, 59.9 years (range: 22-88 years) for male patients, and 56.1 years (range 20-88 years) for female patients. EBER-1 was detected in 24 (7.3%) of the 330 cases, 13 in men (7.5%) and 11 in women (7.0%). The mean age for patients harboring EBER-1-positive gastric carcinomas was 65.3 years: male patients 66.2 years (range: 51-74 years) and female patients 64.4 years (range: 50-84 years). The male/female ratio was 1.1/1 for the entire group and 1.2/1 for those with EBER-1-positive carcinomas.

Pathologic findings
With regard to the anatomic site of the primary neoplasia, 44 (13.3%) carcinomas were localized in the upper-third, 128 (38.8%) were in the middle portion, and 156 (47.3%) were in the lower-third of the stomach. In two cases (one male and one female), the anatomic location could not be determined; the entire stomach showed neoplastic infiltration in the male patient, and information on the original location of primary neoplasia was not available in the female patient. Both cases were EBER-1-negative. The distribution of carcinomas according to anatomic site and histological type, and the anatomic site and histological type of EBER-1-positive carcinomas are shown in Tables 1 and 2, respectively. Fourteen cases corresponded to early carcinomas, and only 4 were confined to mucosa; 10 cases invaded the submucosal layer. The remaining 316 cases were advanced carcinomas affecting muscular, subserosal, and serosal layers, as well as adjacent organs. EBER-1 was positive in all LEL carcinomas, in 4 out of 141 intestinal-type adenocarcinomas and in 11 out of 180 diffuse-type adenocarcinomas. The EBER-1 in situ hybridization signal was uniformly distributed in the nuclei of all 24 positive cases (Figures 1-6). A characteristic

Table 1 Distribution of EBER-1-positive gastric carcinomas by anatomic site and gender

| Anatomic Site | Total (EBER-1+)/total | Males (EBER-1+)/total | Females (EBER-1+)/total |
|--------------|----------------------|-----------------------|------------------------|
| Total        | 24/330               | 13/173                | 11/157                 |
| Upper        | 3/44                 | 3/31                  | 0/13                   |
| Middle       | 13/128               | 7/67                  | 6/61                   |
| Lower        | 8/156                | 3/74                  | 5/82                   |

1In two cases, anatomic location could not be determined. All (one male and one female) were EBER-1-negative.

Table 2 Distribution of EBER-1-positive gastric carcinomas by histologic type and gender

| Histologic Type | Total (EBER-1+)/total | Males (EBER-1+)/total | Females (EBER-1+)/total |
|----------------|----------------------|-----------------------|------------------------|
| I-type         | 4/141                | 3/37                  | 1/43                   |
| Tub1           | 0/12                 | 0/14                  | 0/7                    |
| Tub2           | 4/80                 | 5/44                  | 3/43                   |
| Mac            | 0/19                 | 0/11                  | 0/10                   |
| D-type         | 20/189               | 10/86                 | 10/103                 |
| Por1           | 8/64                 | 3/31                  | 5/33                   |
| Por2           | 2/45                 | 1/21                  | 1/24                   |
| Sig            | 1/71                 | 1/32                  | 0/39                   |
| LEL            | 9/9                  | 4/4                   | 5/5                    |

I-type: Intestinal-type adenocarcinoma; D-type: Diffuse-type adenocarcinoma.
lace pattern was evident in the intramucosal component of three EBER-1-positive carcinomas, two por1 plus tub2 and one tub2 plus por1 adenocarcinomas. Twenty-two of twenty-four EBER-1-positive cases extended beyond the submucosa, whereas two carcinomas, one from a female and one from a male patient, did not exceed the submucosal layer.

There were two EBER-1-negative carcinomas accompanied by EBER-1-positive gastric lesions. The first case, a 52-year-old male patient (Figures 7 and 8), had EBER-1 expression in regenerative epithelium of gastric mucosa adjacent to an EBER-1-negative primary adenocarcinoma (por1). The second case was a 46-year-old female patient whose EBER-1-negative adenocarcinoma (por1) was in the immediate vicinity of dysplastic gastric glands with EBER-1 expression (Figures 9 and 10).

Among the demographic and pathologic variables analyzed, age and histologic type had statistically significant differences, when EBER-1-positive and EBER-1 negative gastric carcinomas were compared (Table 3). In addition, comparison among patients more or less than 60 years of age showed significant differences ($P = 0.008$).

**EBV genotype**

We examined the genotype of seven EBV strains detected from

---

**Figure 1** Moderately differentiated, intestinal-type (tub2) adenocarcinoma. Irregular neoplastic tubular structures are seen throughout the field (hematoxylin and eosin stain).

**Figure 2** Same case as in Figure 1. EBER-1 nuclear positivity is limited to neoplastic cells lining the tubular structures (*in situ* hybridization).

**Figure 3** Diffuse-type (por1) adenocarcinoma. Sheets of neoplastic cells are distributed in an indistinct pattern (hematoxylin and eosin stain).

**Figure 4** Same case as in Figure 3. A uniform nuclear signal of EBER-1 is seen in neoplastic cells (*in situ* hybridization).

**Figure 5** Poorly differentiated, LEL carcinoma. Clusters of neoplastic cells are separated by lymphoplasmacytic infiltrate.

**Figure 6** Same case as in Figure 5. An EBER-1-positive signal is detected in the nuclei of neoplastic cells (*in situ* hybridization).
EBER-1-positive cases; genotype could be determined in five of them. All were type A, wild-type F, and type D. In analysis of the XhoI cleavage site in LMP-1, we found that the cleavage site was lost in four cases and was maintained in one case.

Table 3  Comparison of demographic and pathologic variables between EBER-1-positive and EBER-1-negative gastric carcinomas

|               | EBER-1+/total | OR     | 95%CI    | P      |
|---------------|---------------|--------|----------|--------|
| Gender        |               |        |          |        |
| Female        | 11/157        | 1      | Reference| 0.859  |
| Male          | 13/173        | 0.9    | 0.4-2.2  |        |
| Age (yr)      |               |        |          | 0.013  |
| 20-49         | 0/87          | <0.1   |          |        |
| 50-69         | 14/170        | 0.6    | 0.2-1.3  |        |
| 70-88         | 10/73         | 1      | Reference|        |
| Decade        |               |        |          | 0.787  |
| 1980-1989     | 11/130        | 1      | Reference|        |
| 1990-2000     | 13/200        | 0.9    | 0.4-2.1  |        |
| Tumor site    |               |        |          | 0.229  |
| Cardia        | 3/35          | 1.9    | 0.5-7.5  |        |
| Middle        | 13/137        | 2.2    | 0.9-5.5  |        |
| Antrum        | 8/156         | 1      | Reference|        |
| Lauren classif. |           |        |          | 0.005  |
| Intestinal    | 4/141         | 1      | Reference|        |
| Diffuse       | 20/189        | 4.9    | 1.6-14.8 |        |
| Depth         |               |        |          | 0.273  |
| Early         | 2/14          | 2.4    | 0.5-11.8 |        |
| Advanced      | 22/316        | 1      | Reference|        |

1Odds ratios and 95% confidence intervals were obtained from logistic analysis. Age was adjusted in the analysis of variables other than age.
DISCUSSION

In this study, we found a 7.3% prevalence of EBVaGC in Mexico. In Latin America, this frequency is in contrast with that reported by Koriyama et al. (11.2%)\(^{[24]}\) and Lopes et al. (11.3%)\(^{[21]}\) in Brazil, Carrascal et al., in Colombia (13%)\(^{[22]}\), and Corvalan et al., in Chile (16.8%)\(^{[23]}\). Excluding LEL carcinomas, the prevalence of EBVaGC in Mexico was 4.7%, whereas in Chile it was 15.8%. In a Brazilian study by Koriyama et al.\(^{[29]}\), and a Colombian study by Carrascal et al\(^{[22]}\), there were no LEL carcinomas. Nonetheless, in the study by Lopes et al\(^{[21]}\), a high prevalence of LEL carcinomas (66.7%) among EBVaGC patients was found in a Brazilian population; thus, the prevalence of EBVaGC excluding LEL carcinomas is the lowest (3.8%). Conversely, the prevalence of LEL carcinoma in Mexico was 7.6% in Brazil, 2.7% in Mexico, and 1.1% in Chile. The male/female ratio (1.2/1) was, as previously noted\(^{[3]}\), the lowest among the series reported worldwide. Moreover, after excluding LEL carcinomas, Mexico remains among countries with the low prevalence of EBVaGC worldwide\(^{[6]}\).

The frequency of EBVaGC among GC patients of Mexican ancestry in the USA ranged from 10.2%\(^{[24]}\) to 12%\(^{[25]}\), which is higher than the frequency (7.3%) reported by us. This peculiar migratory phenomenon has also been seen in other countries such as Japan and China. In Japan, the mean frequency of EBVaGC is 6.2%, but among patients of Japanese descent, those who are living in Hawaii, the frequency is 10.2%. In Taiwan, the frequency of EBVaGC among patients of Chinese descent is 11.2%, in comparison to 6.8% in China\(^{[8]}\). This figure probably indicates that besides ethnic and genetic backgrounds, environmental factors are involved in the development of EBVaGC.

A high frequency of EBVaGC at older ages is evident in our Mexican study. Not a single case of EBVaGC was observed among patients aged <50 years. This feature was previously highlighted by Gulley et al\(^{[35]}\), who examined American patients of Mexican descent in the USA and found EBVaGC cases only among those aged 56 years or older. Age dependence of EBVaGC frequency was statistically significant in their study (P = 0.04). The absence of EBVaGC in a set of patients of Mexican ancestry aged <56 years was also reported by Vo et al\(^{[34]}\), although the age difference they reported was not statistically significant. A similar age dependence was reported in China\(^{[29]}\), where EBVaGC frequency was higher among those aged 60 years or older than those aged <60 years (P = 0.03); interestingly, the frequency of EBVaGC (7.8%) in their study is quite similar to that reported by us (7.3%).

In Brazil, Lopes et al\(^{[21]}\), also did not find any patient less than 52 years of age, although other Latin-American studies such as those of Koriyama et al\(^{[24]}\), and Corvalan et al.\(^{[13]}\), did not show any age dependence, reporting EBVaGC cases in patients <50 years. Contrary to the age dependence observed in the present study, a large-scale Japanese study reported a high prevalence of EBVaGC in young men\(^{[27]}\). Furthermore, the same authors showed a significant decreasing trend in EBV prevalence with increasing age for males (P = 0.04). Carrascal et al\(^{[22]}\), also reported an age-dependent decrease of EBVaGC frequency among Colombian individuals with GC (P for trend = 0.022).

The fact that EBV-associated cancer cannot be detected in other digestive tract organs including the colon and esophagus indicates the importance of epithelial change(s) specific to the stomach\(^{[36]}\). EBV-latent infection products were reported to be expressed in predisposing conditions for gastric carcinoma\(^{[29,30]}\). Our observation showing that EBVaGC could not be found among patients <50 years of age supports the involvement of gastric-mucosal changes occurring late in human life in Mexico, as well as in Brazil and China, and relatively early in Japan and Colombia.

EBVaGC has been related to atrophic gastritis, and EBV DNA has been isolated from epithelial cells in gastric mucosa carrying chronic atrophic gastritis\(^{[20-31]}\). Indeed, intestinal metaplasia may enhance EBV entrance into epithelial cells via adherence of the virus to the secretory component of polymeric immunoglobulin A\(^{[35]}\). Our finding of two cases of EBV non-associated gastric carcinoma, one positive for EBER-1 in adjacent hyperplastic mucosa -a finding not previously described- and the other with an EBER-1-positive signal in dysplastic mucosa -a finding originally reported by Shibata and Weiss\(^{[33]}\)- also suggests that the most plausible mechanisms for EBV entry into gastric epithelial cells are those related to previous mucosal damage and cooperation with some unknown promoter factors. In the present study, we did not observe any EBER-1 expression in normal gastric mucosa, even surrounding LEL-EBVaGC or infiltrating lymphocytes. Furthermore, we analyzed endoscopic gastric biopsies from 116 Mexican individuals >40 years of age carrying gastritis with mild atypia, and we did not find any EBER-1-positive case (unpublished data).

In addition to the age dependence of EBVaGC, the present study shows other characteristics of EBVaGC such as distal presentation among female patients and no male preponderance, altogether supporting that ethnicity and genetic backgrounds may address this particular outcome of EBV infection in the Mexican population. Among genetic backgrounds, an immunogenetic constitution may influence the outcome of EBV infection. Human leukocyte antigens (HLA) of the major histocompatibility complex have been implicated in susceptibility to develop EBV-associated malignancies\(^{[34]}\). Very recently, we reported an association between the HLA-DQB1*0501 allele and GC, predominantly in those labeled as diffuse-type carcinomas\(^{[5]}\); unfortunately, EBV status could not be assessed.

In Mexico, EBV antibody prevalence at 4-6 years of age is about 75%\(^{[36]}\). All EBV strains detected in EBVaGC and subjected to EBV genotyping were type A. Previous molecular studies on nasal T-lymphocyte/natural killer-cell lymphomas (nT/NKL) in Mexico\(^{[37]}\) documented that EBV type A (EBV-1) is more frequent than EBV type B (EBV-2), as in nT/NKL and sino-nasal-B-cell lymphomas, and as in reactive tonsils from healthy individuals, thus suggesting that viral infection with EBV-1 strain is highly predominant among the Mexican population. In addition, the same authors\(^{[37]}\) found a similar incidence of EBV LMP-1 deletions in Mexican individuals harboring nT/NKL as compared with normal subjects. Mori et al.\(^{[38]}\), found no significant differences in DNA sequences of the LMP-1 region of EBV strains isolated from EBVaGC patients and throat washing samples of healthy individuals. So far no studies
have revealed differences in the genotype of EBV detected in EBVaGC vs that found in healthy individuals.

In conclusion, EBVaGC occurs less in Mexico than among other Latin-American populations, but it is as frequent in male as it is in female patients >50 years. In Mexican women, EBVaGC affects the middle and distal portions of the stomach but not the proximal portion. Finally, the participation of sequential steps in the mechanism of neoplastic transformation in EBVaGC, in a similar manner to the cascade of events described by Correa[39] in gastric carcinogenesis, cannot be ruled out.

REFERENCES
1 Fuchs CS, Mayer R. Gastric carcinoma. N Engl J Med 1995; 333: 32-41
2 Ohtake-Ocaña LF. Gastric Cancer in Mexico. Gastric Cancer 2001; 4: 162-164
3 Uemura N, Okamoto S, Yamamoto S, Matsunuma N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-789
4 Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49
5 Takada K. Epstein-Barr virus and gastric carcinoma. J Clin Pathol 2000; 53: 255-261
6 Burgess DE, Woodman CB, Flavell KJ, Rowlands DC, Crocker J, Scott K, Biddulph JP, Young LS, Murray PG. Low prevalence of Epstein-Barr virus in incident gastric adenocarcinomas from the United Kingdom. Br J Cancer 2002; 86: 702-704
7 Herrera-Goeppfert R, Reyes E, Hernández-Avila M, Mohar A, Shinkura R, Fujiyama C, Akiba S, Eizuru Y, Harada Y. Epstein-Barr virus-associated gastric carcinoma in Mexico: analysis of 135 consecutive gastrectomies in two hospitals. Mod Pathol 1999; 12: 873-878
8 Japanese Research Society for Gastric Cancer. Japanese Classification of Gastric Carcinoma. 1st English ed. Tokyo Kanehara & Co Ltd 1995: 3
9 Japanese Research Society for Gastric Cancer. Japanese Classification of Gastric Carcinoma. 1st English ed. Tokyo Kanehara & Co Ltd 1995: 39-43
10 Chang KL, Chen YY, Shibata D, Weiss LM. Description of an in situ hybridization methodology for detection of Epstein-Barr virus RNA in paraffin-embedded tissues, with a survey of normal and neoplastic tissues. Diagn Mol Pathol 1992; 1: 246-255
11 Greer CE, Wheeler CM, Manos MM. PCR amplification from paraffin-embedded tissues: sample preparation and the effects of fixation In: Carl WD, and Gabriela SD, eds. PCR primer: a laboratory manual. New York Cold Spring Harbor Laboratory Press 1995: 99-112
12 Afdling HK, Delius H, Freese UK, Clarke J, Bornkamm GW. A putative transforming gene Jijoye virus differs from the family of nuclear proteins. A, Kieff E l. Epstein-Barr virus types 1 and 2 differ in their pathological potential. In: Carl WD, and Gabriela SD, eds. PCR primer: a laboratory manual. New York Cold Spring Harbor Laboratory Press 1995: 99-112
13 Rowe M, Young L, Cadwallader K, Petti L, Kieff E, Richardson A. Distinction between Epstein-Barr virus types A (EBNA-2A) and type B (EBNA-2B) isolates extends to the EBNA-3 family of nuclear proteins. J Virol 1989; 63: 1031-1039
14 Sample J, Young L, Martin B, Chatman T, Kieff E, Richardson A, Kieff E I. Epstein-Barr virus types 1 and 2 differ in their EBNA 3A, EBNA 3B, and ENBA 3C genes. J Virol 1990; 64: 4084-4092
15 Sidagis J, Ueno K, Tokunaga M, Ohyama M, Eizuru Y. Molecular epidemiology of Epstein-Barr virus (EBV) in EBV-related malignancies. Int J Cancer 1997; 72: 72-76
16 Kunimoto M, Tamura S, Tabata T, Yoshie O. One step typ-
33 Shibata D, Weiss LM. Epstein-Barr Virus-associated Gastric Adenocarcinoma. Am J Pathol 1992; 140: 769–774
34 Koriyama C, Shinkura R, Hamasaki Y, Fujiyoshi T, Eizuru Y, Tokunaga M. Human leukocyte antigens related to Epstein-Barr virus-associated gastric carcinoma in Japanese patients. Eur J Cancer Prev 2001; 10: 69-75
35 Herrera-Goepfert R, Zúñiga J, Hernández-Guerrero A, Rodríguez-Reyna T, Osnaya N, Ruiz-Morales J, Vargas-Alarcón G, Yamamoto-Furusho JK, Mohar-Betancourt A, Granados J. Asociación del alelo HLA-DQB1*0501 del complejo principal de histocompatibilidad con cáncer gástrico en México. Gac Med Mex 2004; 140: 299-303
36 Niederman JC, Evans AS. Epstein-Barr virus In: Evans AS, Kaslow RA eds. Viral Infections of Humans: Epidemiology and Control. 4th edition. New York Plenum Medical Book Company 1997: 253-283
37 Elenitoba-Johnson KS, Zarate-Osorno A, Meneses A, Krenacs L, Kingma DW, Raffeld M, Jaffe ES. Cytotoxic granular protein expression, EBV strain type and latent membrane protein-1 oncogene deletions in nasal T-lymphocyte/natural killer cell lymphomas from Mexico. Mod Pathol 1998; 11: 754-761
38 Mori S, Itoh T, Tokunaga M, Eizuru Y. Deletions and single-base mutations within the carboxy-terminal region of the latent membrane protein 1 oncogene in Epstein-Barr virus-related gastric cancers of southern Japan. J Med Virol 1999; 57: 152-158
39 Correa P. Human gastric carcinogenesis: A multistep and multifactorial process. First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52: 6735-6740

Science Editor Guo SY  Language Editor Elsevier HK